Abstract 2072P
Background
Oral mucositis is a debilitating condition seen in head and neck cancer(HNC) patients treated by radiotherapy(RT). The aim of study was to evaluate the response of combined new oral agents as local applicant to prevent mucositisand to record the change in mucositis grading during and after RT.
Methods
Sixty threepatients of post-operative HNC planned for adjuvantRT were randomized to treat mucositis by soda bicarbonate gargles only (Control arm: n=30) 4-5 times a day or soda bicarbonate gargle along with new agent comprised of five drugs (ORA-5GEL): one tablespoon each of honey, choline salicylate ointment(8.7w/w), and lignocaine ointment(2%w/w), one tablet of fluconazole 150mg and metronidazole 400mg were mixed to form a paste and applied intraorally starting from 2nd week of RT (Study arm:n=33).
Results
Severity of mucositis was found to be either stable or in downgrading trend after the application of the ORA-5 gel. None of the patients had grade3 mucositis in study arm compared to 15 patients in control arm. Grade 1 mucositis was seen in 64% and 97% of patients at the end of week 3 that progressed to grade 2 in 27% and 70% patients study and control arm, respectively, by the end of 4thweek (p<0.001). On univariate analysis, factors associated with higher mucositis grading were: high disease burden (Stage IV), conventional RT technique and concurrent chemotherapy. In study arm reversible trend of grading was observed in this subset of patients also. With the continuous use of soda bicarbonate gargle and symptomatic treatment, the frequency of grade 3 mucositis in control arm decreased, however, there was significant difference in grading in both the groups till week 7(p<0.001). By the end of the treatment, none of the patients in control arm had grade 0 mucositis compared to 73% in study arm.
Conclusions
ORA-5 GEL effectively acts on all stages of mucositis and prevents not only severity and progression in all patients but also shows reversible grading during RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Prakash.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06